Biocon Limited has announced a change in the name of its step-down subsidiary. The entity previously known as Biosimilar Collaborations Limited, a subsidiary of Biologics Limited (BBL), has been renamed Ireland Limited. This change took effect on 27 March 2026.

The decision to rename the subsidiary was communicated by Biocon Biologics Limited, a significant subsidiary of Biocon, on 29 March 2026. The updated name reflects the company’s strategic alignment and branding efforts within its international operations.

Biocon Biologics Limited is a key player in the biopharmaceutical sector, focusing on the development and production of biosimilars. The rebranding of its Irish subsidiary aligns with its global expansion and operational strategies.

Further details regarding this change are available on Biocon’s official website, www.biocon.com.

Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).